Cardiovascular Outcomes in Systemic Lupus Erythematosus

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
• Cardiovascular disease (CVE) is a major cause of morbidity and mortality in SLE patients.
• Understanding the temporal evolution of CVE in SLE is crucial for patient management.

Purpose of the Study:

• To review the evolving cardiovascular outcomes (CVE) in patients with systemic lupus erythematosus (SLE).
• To synthesize current knowledge on CVE incidence, risk factors, and management strategies in SLE.
• To highlight the impact of disease activity and treatment on cardiovascular health in SLE.

Main Methods:

• Review of long-term data from inception cohorts.
• Analysis of large population registries.
• Synthesis of studies on risk stratification and primary prevention strategies.

Main Results:

• Mortality and cardiovascular morbidity remain elevated in SLE patients (risk ratio 2-3).
• SLE disease activity-related inflammation increases CVE risk in the first year post-diagnosis.
• Accelerated atherosclerosis contributes to CVE in 25-33% of patients later in the disease course.
• Immunomodulation and disease control are linked to better cardiovascular outcomes.
• Modified risk stratification tools and primary prevention studies (aspirin, hydroxychloroquine) are emerging.

Conclusions:

• Increased awareness of cardiac inflammation in SLE is vital.
• Early disease control and aggressive management of risk factors (hypertension, obesity, high cholesterol) improve outcomes.
• Modified risk stratification can lead to more favorable cardiovascular outcomes in SLE patients.